Population-based BRCA1/2 testing programmes are highly acceptable in the Jewish community: results of the JeneScreen Study
Details
Publication Year 2023-03,Volume 60,Issue #3,Page 265-273
Journal Title
Journal of Medical Genetics
Publication Type
Research article
Abstract
BACKGROUND: Ashkenazi Jewish (AJ) people have a higher incidence of BRCA1/2 pathogenic variants (PVs) than unselected populations. Three BRCA-Jewish founder mutations (B-JFMs) comprise >90% of BRCA1/2 PVs in AJ people. Personal/family cancer history-based testing misses >/=50% of people with B-JFM. METHODS: We compared two population-based B-JFM screening programmes in Australia-using (1) an online tool (Sydney) and (2) in-person group sessions (Melbourne). RESULTS: Of 2167 Jewish people tested (Sydney n=594; Melbourne n=1573), 1.3% (n=28) have a B-JFM, only 2 of whom had a significant cancer family history (Manchester score >/=12). Pretest anxiety scores were normal (mean 9.9+/-3.5 (6-24)), with no significant post-result change (9.5+/-3.3). Decisional regret (mean 7.4+/-13.0 (0-100)), test-related distress (mean 0.8+/2.2 (0-30)) and positive experiences (reverse-scored) (mean 3.4+/-4.5 (1-20)) scores were low, with no significant differences between Sydney and Melbourne participants. Post-education knowledge was good overall (mean 11.8/15 (+/-2.9)) and significantly higher in Melbourne than Sydney. Post-result knowledge was the same (mean 11.7 (+/-2.4) vs 11.2 (+/-2.4)). Participants with a B-JFM had higher post-result anxiety and test-related distress and lower positive experiences, than those without a B-JFM, but scores were within the normal range. Family cancer history did not significantly affect knowledge or anxiety, or pretest perception of B-JFM or cancer risks. Most participants (93%) were satisfied/very satisfied with the programme. CONCLUSION: Both B-JFM screening programmes are highly acceptable to Australian Jewish communities. The programme enabled identification of several individuals who were previously unaware they have a B-JFM, many of whom would have been ineligible for current criteria-based testing in Australia.
Publisher
BMJ
Keywords
Humans; Female; Genetic Testing/methods; Jews/genetics; Genetic Predisposition to Disease; Australia; BRCA1 Protein/genetics; *Neoplasms/genetics; BRCA2 Protein/genetics; *Breast Neoplasms/genetics; Mutation; Ethics; Genetic Counseling; Genetic Testing; Genetics, Population; Heredity
Department(s)
Laboratory Research; Familial Cancer Centre
PubMed ID
36763037
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-07-11 06:23:38
Last Modified: 2024-07-30 02:06:53

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙